leukemia

[Blood] Expression of YBX1 was significantly upregulated in myeloid leukemia cells, and deletion of YBX1 dramatically induced apoptosis and promoted differentiation coupled with reduced proliferation and impaired leukemic capacity of primary human and mouse acute myeloid leukemia cells in vitro and in vivo.

[INmune Bio, Inc.] INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase I clinical trial of its Natural Killer cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome.

[LAVA Therapeutics, N.V.] LAVA Therapeutics N.V. announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-051 in patients with relapsed and/or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

[Blood Cancer Journal] Investigators compared long-term outcomes of 106 patients having T cell mixed chimerism after day 60 and undergoing allogeneic stem cell allograft for acute leukemia from an unrelated donor, with 111 patients having complete chimerism.

[Blood Advances] Untreated older acute myeloid leukemia (AML) patients were randomized to cytarabine and daunorubicin followed by cytarabine consolidation with or without G3139. Addition of G3139 to chemotherapy failed to improve outcomes of older AML patients.

[Cell Reports] Using a murine chronic myeloid leukemia (CML) model, investigators examined leukemia-induced alterations in mesenchymal cell populations and showed that 6C3+ stromal progenitors expanded in CML bone marrow and exhibited increased leukemia stem cells but reduced HSC supportive capacity.